StudyFinder

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure

Status: Recruiting

This study is being done to learn more about maridebart cafraglutide (MariTide [formerly AMG 133]) for people with heart failure (HF) and obesity in addition to their routine medical care. Participants will receive treatment with either MariTide or a placebo, which will be called a study drug. A placebo looks the same as the investigational medicine but contains no actual medicine.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Age ≥ 18 years
• BMI ≥ 30 kg/m2 at screening
• diagnosis of heart failure
• NYHA Class II-IV
• left ventricular ejection fraction of of at least 40%
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• Type 1 diabetes
• acute or chronic hepatitis
• history of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior, any prior suicide attempt, or history of self injury in past 5 years
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions:

Heart & Vascular

Keywords:

body mass index (BMI) 30 kg/m2, Clinics and Surgery Center (CSC), heart failure (HF) with preserved or mildly reduced EF, obesity

Study Contact: Gretchen Peichel - gpeichel@umn.edu
Principal Investigator: Tamas Alexy
Phase: PHASE3
IRB Number: STUDY00026740
See this study on ClinicalTrials.gov

Back